IMPACT OF SOLIFENACIN ON SYMPTOM BOTHER, HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, TREATMENT SATISFACTION, AND SYMPTOMS IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM VIBRANT

被引：0

作者：

Mitcheson, H. D. ^{[1
]}

Roy, J. B. ^{[2
]}

Gilmet, G. ^{[3
]}

Marshall, T. S. ^{[3
]}

Shannon, J. B. ^{[4
]}

机构：

[1] Bay State Clin Trials Inc, Watertown, MA USA

[2] Edmond Med Ctr, Edmond, OK USA

[3] Astellas Pharma US Inc, Deerfield, IL USA

[4] GlaxoSmithKline Inc, Res Triangle Pk, NC USA

来源：

VALUE IN HEALTH | 2009年 / 12卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)74067-5

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A201 / A201

页数：1

共 50 条

[1] Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study
Crosby, R. D.
Mathias, S. D.
Marshall, T. S.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (02) : 211 - 218
[2] Solifenacin for overactive bladder with incontinence: Symptom bother and health-related quality of life outcomes
Garely, Alan D.
Lucente, Vincent
Vapnek, Jonathan
Smith, Neila
ANNALS OF PHARMACOTHERAPY, 2007, 41 (03) : 391 - 399
[3] RELATIONSHIPS BETWEEN CHANGES IN OVERACTIVE BLADDER (OAB) SYMPTOMS AND IN SUBJECTIVE ASSESSMENTS OF SYMPTOM BOTHER AND HEALTH-RELATED QUALITY OF LIFE (HRQL) IN PATIENTS TAKING SOLIFENACIN OR PLACEBO IN THE VIBRANT STUDY
Crosby, R. D.
Mathias, S. D.
Marshall, T.
EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 249 - 250
[4] SOLIFENACIN SIGNIFICANTLY IMPROVES SYMPTOM BOTHER, HEALTH-RELATED QUALITY OF LIFE, AND OTHER PATIENT-REPORTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM VIBRANT, A LARGE PLACEBO-CONTROLLED TRIAL
Young, D. G.
Samuels, T.
Vardy, M. D.
Gilmet, G.
Marshall, T.
Shannon, J.
JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 172 - 172
[5] Characterization of Symptom Bother and Health-related Quality of Life in Japanese Female Patients With Overactive Bladder
Gotoh, Momokazu
Kobayashi, Toshimitsu
Sogabe, Keizo
NEUROUROLOGY AND URODYNAMICS, 2015, 34 (08) : 730 - 735
[6] Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare Open-Label Trial (VOLT)
Garely, Alan D.
Kaufman, Joel M.
Sand, Peter K.
Smith, Nella
Andoh, Masakazu
CLINICAL THERAPEUTICS, 2006, 28 (11) : 1935 - 1946
[7] CHARACTERIZATION OF SYMPTOM BOTHER, HEALTH-RELATED QUALITY OF LIFE, AND PATIENT'S SATISFACTION TO BLADDER CONDITION IN 967 JAPANESE FEMALE PATIENTS WITH OVERACTIVE BLADDER
Gotoh, M.
Kobayashi, T.
Sogabe, K.
NEUROUROLOGY AND URODYNAMICS, 2013, 32 (06) : 851 - 852
[8] The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS
Coyne, Karin S.
Sexton, Chris C.
Kopp, Zoe S.
Ebel-Bitoun, Caty
Milsom, Ian
Chapple, Chris
BJU INTERNATIONAL, 2011, 108 (09) : 1459 - 1471
[9] Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine
Coyne, K. S.
Elinoff, V.
Gordon, D. A.
Deng, D. Y.
Brodsky, M.
Glasser, D. B.
Jumadilova, Z.
Carlsson, M.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (06) : 925 - 931
[10] Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q)
Gotoh, Momokazu
Kobayashi, Toshimitsu
Sogabe, Keizo
INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (05) : 505 - 511

← 1 2 3 4 5 →